(Q38285859)

1 September 2017

1 reference

title

The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy (English)

1 reference

1 September 2017

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25491730%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Simone Muenst

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25491730%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

Savas D Soysal

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25491730%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

author name string

Sylvia Hoeller

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25491730%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

language of work or name

English

0 references

publication date

10 December 2014

1 reference

Expert Opinion on Therapeutic Targets

1 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25491730%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25491730%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25491730%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

page(s)

201-211

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25491730%20AND%20SRC:MED&resulttype=core&format=json

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy

11 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Programmed death-1 pathway in cancer and autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

CTLA-4 can function as a negative regulator of T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Structural and functional analysis of the costimulatory receptor programmed death-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

The PD-1/PD-Ls pathway and autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

PD-L2 is a second ligand for PD-1 and inhibits T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

The role of the PD-1 pathway in autoimmunity and peripheral tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Costimulator B7-DC attenuates strong Th2 responses induced by Nippostrongylus brasiliensis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

PD-1 and its ligands in tolerance and immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Recent insights into the role of the PD-1/PD-L1 pathway in immunological tolerance and autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Enhancing SIV-specific immunity in vivo by PD-1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Human prostate-infiltrating CD8+ T lymphocytes are oligoclonal and PD-1+.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

FOXP3+ Tregs and B7-H1+/PD-1+ T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Inhibitory B7-family molecules in the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Diagnostic and prognostic utility of PD-1 in B cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Programmed death-1 (PD-1) is a marker of germinal center-associated T cells and angioimmunoblastic T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Differential expression of PD-L1 and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of lymphohematopoietic tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Comprehensive molecular characterization of gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Postoperative adjuvant chemotherapy use in patients with stage II/III rectal cancer treated with neoadjuvant therapy: a national comprehensive cancer network analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Programmed death ligand-1 expression in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Overall survival and PD-L1 expression in metastasized malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: correlation with important high-risk prognostic factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Ties that bind: p16 as a prognostic biomarker and the need for high-accuracy human papillomavirus testing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

PD-1-Expressing Tumor-Infiltrating T Cells Are a Favorable Prognostic Biomarker in HPV-Associated Head and Neck Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.980235

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death

21 January 2018

1 reference

24 May 2022

https://opencitations.net/index/coci/api/v1/citations/10.1002/J.1460-2075.1992.TB05481.X

Identifiers

DOI

10.1517/14728222.2014.980235

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25491730%20AND%20SRC:MED&resulttype=core&format=json

11 June 2020

1 reference